Health & Wellness News

Pfizer, Blackstone Life Sciences Enter Strategic Funding Agreement for GLP-1

0 3


Key takeaways:

  • Blackstone Life Sciences will provide Pfizer up to $1.5 billion through 2028 to fund development costs for berobenatide.
  • The investigational monthly GLP-1 receptor agonist is being evaluated in phase 3 trials for obesity-related comorbidities, including OSA.
  • Pfizer retains full operational control of the clinical program, while Blackstone is eligible for milestone-based payments upon regulatory approval and commercial sales.

Pfizer Inc and Blackstone Life Sciences recently entered into a strategic co-funding agreement under which funds managed by Blackstone will pay up to $1.5 billion of development costs through 2028 for berobenatide. Berobenatide is an investigational, potential first-in-class monthly GLP-1 receptor agonist peptide being studied for chronic weight management and obesity-related conditions, including obstructive sleep apnea.

In exchange for the funding, Blackstone will be eligible to receive milestone-based payments, subject to US regulatory approval of monthly dosing of injectable berobenatide monotherapy for chronic weight management, as well as the achievement of certain commercial sales milestones. Under the agreement, Pfizer retains full operational control and decision-making regarding the berobenatide program, and Blackstone does not acquire any rights or ownership in the drug.

“Our aim is to bring important new medicines to patients while taking a disciplined approach that pairs internal research investments with targeted investment from capital partners,” says Cecile Guegan, chief financial officer and executive vice president at Pfizer, in a release.

“This collaboration is a good example of our leadership in providing capital solutions at scale to advance important medicines and technologies to patients,” says Nicholas Galakatos, global head of Blackstone Life Sciences, in a release.

Looking ahead, Pfizer plans to advance more than 20 trials for obesity and related comorbidities in 2026. This includes 10 ongoing and planned phase 3 trials for berobenatide (PF’3944), including evaluations for obstructive sleep apnea and knee osteoarthritis. The development program evaluates berobenatide both as a monotherapy and in combination with various Nutrient-Stimulated Hormone peptides, including amylin analogs.

ID 21817087© Jerryb8| Dreamstime.com


More in GLP-1 Discoveries for Sleep Apnea:



Source link

Advertisement

Leave A Reply

Your email address will not be published.